Crystal form of compound and use thereof
Patent Information
- Application Number
- MYPI2025008518
- Authority / Receiving Office
- MY · MY
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-07-10
- Filing Date
- 2024-06-27
- Publication Date
- 2025-01-10
AI Technical Summary
During the development and application of existing rifamycin derivatives is limited by their physical and chemical properties such as high relative molecular weight, high fat solubility, low water solubility and hygroscopicity, which makes it difficult to meet the drug properties of the preparations, affecting their bioavailability. and stability.
Provides free alkali crystal forms A and B of a compound, identified by X-ray powder diffraction and differential scanning calorimetry, and crystallizes in methanol or toluene solvents to form stable water-free Or solvate-free, improving its medicinal significance.
The stability and bioavailability of the compounds have been improved, the drug properties of the formulations have been met, and pharmaceutical compositions and kits are provided for preventing, treating or alleviating diseases caused by bacterial infections, which have enhanced the activity against microorganisms.
Smart Images

Figure PI2025008518_DRAWING_001 
Figure PI2025008518_DRAWING_002 
Figure PI2025008518_DRAWING_003
Abstract
Description
Crystal form of compound and use thereof Technical Field
[0001] The present application relates to the field of biomedicine, and specifically to a crystal form of a compound and its use. Background Art
[0002] Rifamycin is a natural product with potential antimicrobial activity. Rifamycins of natural origin (such as rifamycin B, rifamycin O, rifamycin R, rifamycin U, rifamycin S, rifamycin SV and rifamycin Y (Brufani, M., Cerrini, S., Fedeli, W., Vaciago, AJ Mol. Biol. 1974, 87, 409-435)) have limited therapeutic applications, such as poor pharmacokinetics, low oral bioavailability, weak activity against gram-negative pathogens and low distribution in infected tissues. Prior art has produced various semi-synthetic rifamycin derivatives with improved antimicrobial spectrum and pharmacological properties through chemical modification. Among these semi-synthetic compounds, for example rifampicin and rifabutin have been developed into therapeutic drugs, currently used to treat tuberculosis and other microbial infections (Farr, B.M.Rifamycins, in Principles and Practice of Infectious Diseases; Mandell, GL, Bennett, J.E., Dolin, R., Eds.; Churchill Livingstone Philadelphia; pp. 348-361). TNP-2198 is a dual-targeted rifamycin-nitroimidazole conjugate, which has potent activity against microaerophilic and anaerobic bacterial pathogens, and shows good activity against strains resistant to both rifamycin and nitroimidazole. However, this class of innovative drug molecules with antimicrobial activity is often subject to the effects of the high relative molecular weight, high fat solubility, low water solubility and hygroscopicity of its free form, as well as bioavailability and stability (chemical stability, thermal stability, melting point, crystal stability) of its free form, and is difficult to meet the drugability requirements of the formulation. Therefore, finding and screening new molecular entities (such as salt forms or crystal forms) of such prototype drug molecules plays a vital role in realizing their medicinal significance.
[0003] Summary of the Invention
[0004] In order to overcome the deficiencies of the prior art, the present invention provides a free base crystalline form of a compound that can meet multiple pharmaceutical needs.
[0005] On the one hand, the present application provides a crystalline form A of the free base of the compound represented by formula (I),
[0006] The X-ray powder diffraction of the crystalline form A has characteristic peaks at diffraction angles 2θ of 5.28°±0.2°, 7.17°±0.2°, 8.50°±0.2°, 10.66°±0.2°, 14.33°±0.2°, 15.84°±0.2° and 18.60°±0.2°.
[0007] In some embodiments, the crystalline form A has characteristic peaks at one or more of the diffraction angle 2θ values of 12.61°±0.2°, 14.83°±0.2°, 15.26°±0.2°, 16.57°±0.2°, 19.97°±0.2° and 21.97°±0.2°.
[0008] In some embodiments, the crystalline form A has characteristic peaks at diffraction angles 2θ of 12.61°±0.2°, 14.83°±0.2°, 15.26°±0.2°, 16.57°±0.2°, 19.97°±0.2° and 21.97°±0.2°.
[0009] In some embodiments, the X-ray powder diffraction (XRPD) pattern of Form A is substantially consistent with FIG1 .
[0010] In some embodiments, the differential scanning calorimetry curve of the crystalline Form A has an endothermic peak at about 169.3°C.
[0011] In some embodiments, the differential scanning calorimetry (DSC) graph of Form A is substantially consistent with Figure 2B.
[0012] In some embodiments, the crystalline Form A is an anhydrate.
[0013] On the other hand, the present application provides a crystalline form A of the free base of the compound represented by formula (I), wherein the differential scanning calorimetry curve of the crystalline form A has an endothermic peak at about 169.3°C.
[0014] In some embodiments, the differential scanning calorimetry (DSC) graph of Form A is substantially consistent with Figure 2B.
[0015] In some embodiments, the crystalline Form A is an anhydrate and / or ansolvate-free.
[0016] On the other hand, the present application provides a crystalline form B of the free base of the compound represented by formula (I), and the X-ray powder diffraction of the crystalline form B has characteristic peaks at diffraction angles 2θ of 4.89°±0.2°, 6.67°±0.2°, 7.12°±0.2°, 13.41°±0.2°, 14.62°±0.2°, 15.19°±0.2° and 18.23°±0.2°.
[0017] In some embodiments, the X-ray powder diffraction of the crystalline form B has characteristic peaks at one or more of the diffraction angles 2θ of 7.84°±0.2°, 10.67°±0.2°, 14.25°±0.2°, 16.07°±0.2°, 17.10°±0.2°, 17.41°±0.2°, 17.74°±0.2° and 20.73°±0.2°.
[0018] In some embodiments, the X-ray powder diffraction of the crystalline form B has characteristic peaks at diffraction angles 2θ of 7.84°±0.2°, 10.67°±0.2°, 14.25°±0.2°, 16.07°±0.2°, 17.10°±0.2°, 17.41°±0.2°, 17.74°±0.2° and 20.73°±0.2°.
[0019] In some embodiments, the X-ray powder diffraction (XRPD) pattern of Form B is substantially consistent with FIG. 3 .
[0020] In some embodiments, the differential scanning calorimetry curve of Form B has endothermic peaks at about 85.6°C, about 130.7°C, and about 144.3°C.
[0021] In some embodiments, the differential scanning calorimetry (DSC) graph of Form B is substantially consistent with Figure 4B.
[0022] In some embodiments, the Form B is obtained by converting the Form A described herein in a toluene reagent.
[0023] In some embodiments, the crystalline Form B is a toluene solvate.
[0024] In some embodiments, the molar ratio of the compound represented by formula (I) in the crystalline form B to toluene molecules is 1:2 to 1:1.
[0025] On the other hand, the present application provides a crystalline form B of the free base of the compound represented by formula (I), wherein the differential scanning calorimetry curve of the crystalline form B has endothermic peaks at about 85.6°C, about 130.7°C and about 144.3°C.
[0026] In some embodiments, the differential scanning calorimetry (DSC) graph of Form B is substantially consistent with Figure 4B.
[0027] In some embodiments, the Form B is obtained by converting the Form A described herein in a toluene reagent.
[0028] In some embodiments, the crystalline Form B is a toluene solvate.
[0029] In some embodiments, the molar ratio of the compound represented by formula (I) in the crystalline form B to toluene molecules is 1:2 to 1:1.
[0030] On the other hand, the present application provides a pharmaceutical composition, comprising the crystalline form A described herein and / or the crystalline form B described herein, and optionally a pharmaceutically acceptable carrier.
[0031] In some embodiments, the pharmaceutical composition further comprises a second therapeutic agent.
[0032] In some embodiments, the second therapeutic agent is selected from the group consisting of proton pump inhibitors, acid suppressants, efflux pump inhibitors, anesthetics, antifungals, antivirals, antibacterials, antiprotozoals, anti-inflammatory drugs, anticoagulants, platelet aggregation inhibitors, antipyretics, lipid-lowering agents, and zinc salts.
[0033] On the other hand, the present application provides a kit comprising one or more of the crystalline form A described herein, the crystalline form B described herein, and the pharmaceutical composition described herein.
[0034] In some embodiments, the kit further comprises instructions in physical form and / or machine-readable electronic form.
[0035] On the other hand, the present application provides a method for preparing a drug using the crystal form A described herein and / or the crystal form B described herein.
[0036] On the other hand, the present application provides a method for inhibiting or preventing bacterial growth, which comprises administering an effective amount of one or more of the crystalline form A described herein, the crystalline form B described herein, the pharmaceutical composition described herein, and the kit described herein.
[0037] On the other hand, the present application provides a method for preventing, treating or alleviating a disease or a related condition thereof, the method comprising administering to a patient in need thereof an effective amount of one or more of the crystalline form A described herein, the crystalline form B described herein, the pharmaceutical composition described herein and the kit described herein.
[0038] In some embodiments, the patient in need thereof has a bacterial infection.
[0039] In some embodiments, the bacteria is selected from the group consisting of Helicobacter pylori, Mycobacterium tuberculosis, nontuberculous mycobacteria, Acinetobacter baumannii, Bacteroides fragilis, Bifidobacterium longum, Ruminococcus, Prevotella, Clostridium perfringens, Clostridium difficile, Lactobacillus acidophilus, Eggertella lentus, Fusobacterium nucleatum, Gardnerella vaginalis, Mobiluncus dispiritus, Peptostreptococcus, Porphyromonas insaccharolyticus, Prevotella diversa, Propionibacterium acnes, and Veillonella parvum.
[0040] On the other hand, the present application provides the use of the crystalline form A described herein, the crystalline form B described herein, the pharmaceutical composition described herein and / or the kit described herein for inhibiting or preventing bacterial growth.
[0041] On the other hand, the present application provides the use of the crystalline form A described herein, the crystalline form B described herein, the pharmaceutical composition described herein and / or the kit described herein for preparing a drug, which is used to prevent, treat or alleviate diseases caused by bacterial infection or related conditions thereof.
[0042] In some embodiments, the bacteria is selected from the group consisting of Helicobacter pylori, Mycobacterium tuberculosis, nontuberculous mycobacteria, Acinetobacter baumannii, Bacteroides fragilis, Bifidobacterium longum, Ruminococcus, Prevotella, Clostridium perfringens, Clostridium difficile, Lactobacillus acidophilus, Eggertella lentus, Fusobacterium nucleatum, Gardnerella vaginalis, Mobiluncus dispiritus, Peptostreptococcus, Porphyromonas insaccharolyticus, Prevotella diversa, Propionibacterium acnes, and Veillonella parvum.
[0043] In some embodiments, the disease or its associated condition is selected from the group consisting of: gastritis, gastric ulcer, bacterial vaginosis, diarrhea, pneumonia, appendicitis, cholecystitis, otitis media, endocarditis, endometritis, brain abscess, myocardial necrosis, osteomyelitis, peritonitis, empyema, salpingitis, septic arthritis, liver abscess, sinusitis, pelvic inflammatory disease, and bacteremia; and upper respiratory tract infection, lower respiratory tract infection, skin and soft tissue infection, bone and joint infection, lung infection, abdominal infection, eye infection, ear infection, oral infection, and surgical infection.
[0044] On the other hand, the present application provides the pharmaceutical composition or the kit described herein, which is used to prevent, treat or alleviate diseases caused by bacterial infection or related conditions thereof.
[0045] In some embodiments, the bacteria is selected from the group consisting of Helicobacter pylori, Mycobacterium tuberculosis, nontuberculous mycobacteria, Acinetobacter baumannii, Bacteroides fragilis, Bifidobacterium longum, Ruminococcus, Prevotella, Clostridium perfringens, Clostridium difficile, Lactobacillus acidophilus, Eggertella lentus, Fusobacterium nucleatum, Gardnerella vaginalis, Mobiluncus dispiritus, Peptostreptococcus, Porphyromonas insaccharolyticus, Prevotella diversa, Propionibacterium acnes, and Veillonella parvum.
[0046] In some embodiments, the disease or its associated condition is selected from the group consisting of: gastritis, gastric ulcer, bacterial vaginosis, diarrhea, pneumonia, appendicitis, cholecystitis, otitis media, endocarditis, endometritis, brain abscess, myocardial necrosis, osteomyelitis, peritonitis, empyema, salpingitis, septic arthritis, liver abscess, sinusitis, pelvic inflammatory disease, and bacteremia; and upper respiratory tract infection, lower respiratory tract infection, skin and soft tissue infection, bone and joint infection, lung infection, abdominal infection, eye infection, ear infection, oral infection, and surgical infection.
[0047] On the other hand, the present application provides a method for preparing the crystalline form A described in the present application, which comprises crystallizing the compound represented by formula (I) in a solvent comprising an alcohol solvent, wherein the alcohol solvent is selected from one or more of methanol, ethanol, n-propanol, isopropanol, n-butanol, isobutanol and tert-butanol.
[0048] Furthermore, the method for preparing Form A described in the present application further comprises crystallizing the compound represented by formula (I) in an alcohol solvent.
[0049] In some embodiments, the alcohol solvent is methanol, ethanol, or a combination thereof.
[0050] In some embodiments, the method further comprises concentrating the alcohol solvent to obtain a concentrated wet product, and drying the concentrated wet product.
[0051] On the other hand, the present application provides a crystalline form A of the free base of the compound represented by formula (I), wherein the crystalline form A is obtained by the method for preparing the crystalline form A described in the present application.
[0052] On the other hand, the present application provides a method for preparing the crystalline form B described herein, which comprises crystallizing the crystalline form A described herein in toluene solvent.
[0053] On the other hand, the present application provides a crystalline form B of the free base of the compound represented by formula (I), wherein the crystalline form B is obtained by the method for preparing the crystalline form B described in the present application.
[0054] Those skilled in the art can easily discern other aspects and advantages of the present application from the detailed description below. In the detailed description below, only exemplary embodiments of the present application are shown and described. As will be appreciated by those skilled in the art, the content of this application enables those skilled in the art to modify the disclosed specific embodiments without departing from the spirit and scope of the invention to which this application relates. Accordingly, the descriptions in the drawings and specification of this application are merely exemplary and not restrictive. BRIEF DESCRIPTION OF THE DRAWINGS
[0055] The specific features of the inventions of this application are set forth in the appended claims. The features and advantages of the inventions of this application can be better understood by referring to the exemplary embodiments described in detail below and the accompanying drawings. A brief description of the drawings is as follows:
[0056] FIG1 shows the XRPD pattern of Form A of the present application.
[0057] 2A-2B show the TGA graph and DSC graph of Form A of the present application.
[0058] FIG3 shows the XRPD pattern of Form B of the present application.
[0059] 4A-4B show the TGA graph and DSC graph of Form B of the present application.
[0060] Figure 5 shows the crystal form A of the present application 1 H NMR spectrum.
[0061] FIG6A-FIG6B show the PLM observation results of Form A of the present application.
[0062] Figures 7A-7C show the initial crystal form B of the present invention and the crystals heated to 115°C and 140°C, respectively. 1 H NMR spectrum.
[0063] FIG8 shows the XRPD overlay comparison results of Form B of the present application before and after heating.
[0064] 9A-9C show the XRPD patterns of the crystalline forms C1, C2 and C3 of the present application.
[0065] FIG9D shows the XRPD patterns of Forms C1, C2, and C3 after drying.
[0066] FIG10 shows the DVS experimental analysis results of Form A of the present application.
[0067] FIG11 shows the XRPD overlay comparison results of Form A of the present application before and after DVS testing.
[0068] FIG12 shows the XRPD overlay comparison results of Form A of the present application in the solid stability evaluation.
[0069] FIG13 shows the HPLC stacked comparison results of the solid stability evaluation of Form A of the present application.
[0070] FIG14 shows the structural formula of the impurity RRT0.98 in the crude product of the compound of formula (I) of the present application. DETAILED DESCRIPTION
[0071] The following describes the implementation of the present invention through specific embodiments. People familiar with this technology can easily understand other advantages and effects of the present invention from the contents disclosed in this specification.
[0072] Definition of terms
[0073] In this application, the term "substantially consistent with (Figure)..." generally refers to information such as the number of characteristic peaks in the spectrum, the position (or distribution) of the characteristic peaks, and the geometric topological regularity being substantially the same or similar. For example, the characteristic peaks referred to in this application may be diffraction peaks in an X-ray powder diffraction (XRPD) spectrum, endothermic peaks in a differential scanning calorimetry (DSC) spectrum, or endothermic peaks in a nuclear magnetic resonance (NMR) spectrum. 1 1H NMR) spectrum or absorption peaks in a high performance liquid chromatography (HPLC) spectrum, etc. For example, the term "substantially consistent with (a graph)..." may mean that at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% of the characteristic peaks in the spectrum are shown in the referenced graph.
[0074] In this application, the term "2θ (also known as 2thIIta or diffraction peak) value" related to the X-ray powder diffraction (XRPD) pattern is in degrees (°). When referring to the spectrum and / or data in the diagram, the term "diffraction peak" generally refers to a feature that a person skilled in the art would not attribute to background noise. The X-ray powder diffraction peaks of the crystalline form described in this application may have experimental errors in the measurement of the 2θ or diffraction peaks of the X-ray powder diffraction pattern. The error may occur between one machine and another and between one sample and another. The measurement of the 2θ or diffraction peak of the X-ray powder diffraction pattern may be slightly different. The numerical value of the experimental error or difference may be ±0.2 units or ±0.1 units or ±0.05 units. Therefore, the numerical value of the 2θ or diffraction peak cannot be regarded as absolute.
[0075] In certain embodiments, the differential scanning calorimetry (DSC) curve of the crystalline form may also have experimental errors, which may occur between one machine and another and between one sample and another. The position and peak value of the endothermic peak may be slightly different. The numerical value of the experimental error or difference may be less than or equal to 5°C, or less than or equal to 4°C, or less than or equal to 3°C, or less than or equal to 2°C, or less than or equal to 1°C. Therefore, the peak position or peak value of the DSC endothermic peak cannot be considered absolute.
[0076] In certain embodiments, the thermogravimetric analysis (TGA) of the crystalline form may also have experimental errors, which may occur between one machine and another and between one sample and another. The weight loss temperature and the amount of weight loss may be slightly different. The numerical value of the experimental error or difference may be about ±0.1 unit, about ±0.05 unit, or about ±0.01 unit. Therefore, the numerical values of the weight loss temperature and the amount of weight loss cannot be considered absolute.
[0077] Throughout this application, all numerical values disclosed herein are approximate, regardless of whether the word "about" or "approximately" is used. The numerical value of each numeral may vary by, for example, ±1%, ±2%, or ±5%. The term "about" or "approximately" refers to an acceptable error range for a particular value, typically determined by one of ordinary skill in the art, which depends in part on how the value is measured or determined, i.e., the limitations of the measurement system. For example, "about" or "approximately" can mean within 1 or more standard deviations, as practiced in the art. Alternatively, "about" or "approximately" can mean a range of up to 10% or 20% (i.e., ±10% or ±20%). For example, about 3 mg can include any amount between 2.7 mg and 3.3 mg (for 10%) or between 2.4 mg and 3.6 mg (for 20%). Furthermore, particularly with respect to biological systems or processes, the term can mean a value of up to an order of magnitude or up to a factor of 5. When particular values or compositions are provided in the specification and appended claims, unless otherwise indicated, the meaning of "about" or "approximately" should be assumed to be within an acceptable error range for that particular value or composition.
[0078] In this application, the terms "solvate" and "solvate" are used interchangeably and generally refer to an association or complex of one or more solvent molecules with the compounds described herein. Examples of solvents that form solvates include, but are not limited to, water, isopropanol, ethanol, methanol, DMSO, ethyl acetate, acetic acid, and ethanolamine.
[0079] In this application, the term "pharmaceutically acceptable carrier" generally refers to one or more non-toxic materials that do not interfere with the effectiveness of the biological activity of the active ingredient. Such preparations can conventionally contain salts, buffers, preservatives, compatible carriers and optionally other therapeutic agents. Such pharmaceutically acceptable preparations can also include compatible solid or liquid fillers, diluents or encapsulating materials suitable for administration to people. Other envisioned carriers, excipients, and / or additives that can be used in the formulations described herein may include, for example, flavorings, antimicrobials, sweeteners, antioxidants, antistatic agents, lipids, protein excipients (such as serum albumin, gelatin, casein), salt-forming counterions (such as sodium), etc. These and other known pharmaceutical carriers, excipients and / or additives suitable for use in the formulations described herein are known in the art and are listed, for example, in "Remington: The Science & Practice of Pharmacy," 21st edition, Lippincott Williams & Wilkins (2005) and "Physician's Desk Reference," 60th edition, Medical Economics, Montvale, New Jersey (2005). Suitable pharmaceutically acceptable carriers can be routinely selected for the desired or required mode of administration, solubility and / or stability.
[0080] In this application, the term "therapeutic agent" generally refers to a compound (including but not limited to pharmaceutically acceptable salts, hydrates, solvates, crystal forms, prodrugs, metabolites or deuterated substances thereof), a mixture of compounds, a composition, a biomacromolecule or an extract made from biological materials that can induce a desired therapeutic effect, prevent a certain disease, or alleviate a related disease when properly administered to a patient.
[0081] In the present application, the term "bacteria" generally refers to a class of prokaryotes that do not have obvious nuclei and membranous organelles. The bacterium can include spherical, rod-shaped, spiral-shaped. The bacterium can include species that grow in an interlike manner, such as Escherichia, Salmonella, Shigella, Klebsiella, Vibrio, Pasteurella, Borrelia, Leptospira, Campylobacter, Clostridium, Corynebacterium, Yersinia, Treponema, Rickettsia, Chlamydia, and the like. Bacteria include, but are not limited to, bacterial infections, infections caused by bacteria, and the like. Bacteria include, but are not limited to, infections caused by bacteria, and the like. Bacteria include, but are not limited to, infections caused by bacteria, and the like. Bacteria include, but are not limited to, infections caused by bacteria, and the like. Bacteria include, but are not limited to, infections caused by bacteria, and the like. Bacteria include, but are not limited to, infections caused by bacteria, and the like. Bacteria include, but are not limited to, infections caused by bacteria, and the like. Bacteria include, but are not limited to, infections caused by bacteria, and the like.
[0082] In this application, the term "patient in need thereof" generally includes human patients and other mammalian subjects receiving prophylactic or therapeutic treatment, including but not limited to non-human primates, experimental animals such as rabbits, dogs, rats and mice, and other animals. These "patients in need thereof" can be, for example, subjects with a confirmed specific disease, subjects receiving treatment related to a specific disease, subjects with a tendency or risk of developing a specific disease, etc.
[0083] In this application, the term "administer" generally refers to introducing the drug or a composition comprising the drug (e.g., a therapeutic agent provided herein) into the patient's body by any introduction or delivery route. Any method known to those skilled in the art for contacting cells, organs, or tissues with the drug or its composition can be used.
[0084] As used herein, the term "effective amount" generally refers to an amount sufficient to achieve or at least partially achieve the desired therapeutic effect. An "effective amount" of a drug or therapeutic agent generally refers to an amount sufficient to cure or at least partially prevent the disease and its complications in a patient already suffering from the disease. The effective amount for this purpose will depend on the severity of the infection and the overall state of the patient's own immune system.
[0085] In this application, the term "comprising" generally refers to including the features specified but not excluding other elements. The terms "above" and "below" generally refer to including the number.
[0086] In this application, the term "selected from" generally refers to the selected objects and all combinations thereof. For example, "selected from (:) A, B and C" means all combinations of A, B and C, for example, A, B, C, A+B, A+C, B+C or A+B+C.
[0087] Detailed Description of the Invention
[0088] On the one hand, the present application provides a crystalline form A of the free base of the compound represented by formula (I), wherein the X-ray powder diffraction of the crystalline form A has characteristic peaks at diffraction angles 2θ of 5.28°±0.2°, 7.17°±0.2°, 8.50°±0.2°, 10.66°±0.2°, 14.33°±0.2°, 15.84°±0.2° and 18.60°±0.2°.
[0089] On the other hand, the present application provides a crystalline form A of the free base of the compound represented by formula (I), wherein the differential scanning calorimetry curve of the crystalline form A has an endothermic peak at about 169.3°C.
[0090] On the other hand, the present application provides a crystalline form B of the free base of the compound represented by formula (I), and the X-ray powder diffraction of the crystalline form B has characteristic peaks at diffraction angles 2θ of 4.89°±0.2°, 6.67°±0.2°, 7.12°±0.2°, 13.41°±0.2°, 14.62°±0.2°, 15.19°±0.2° and 18.23°±0.2°.
[0091] On the other hand, the present application provides a crystalline form B of the free base of the compound represented by formula (I), wherein the differential scanning calorimetry curve of the crystalline form B has endothermic peaks at about 85.6°C, about 130.7°C and about 144.3°C.
[0092] On the other hand, the present application provides a pharmaceutical composition, comprising the crystalline form A described herein and / or the crystalline form B described herein, and optionally a pharmaceutically acceptable carrier.
[0093] On the other hand, the present application provides a kit comprising one or more of the crystalline form A described herein, the crystalline form B described herein, and the pharmaceutical composition described herein.
[0094] On the other hand, the present application provides a method for preparing a drug using the crystal form A described herein and / or the crystal form B described herein.
[0095] On the other hand, the present application provides a method for inhibiting or preventing bacterial growth, which comprises administering an effective amount of one or more of the crystalline form A described herein, the crystalline form B described herein, the pharmaceutical composition described herein, and the kit described herein.
[0096] On the other hand, the present application provides a method for preventing, treating or alleviating a disease or a related condition thereof, the method comprising administering to a patient in need thereof an effective amount of one or more of the crystalline form A described herein, the crystalline form B described herein, the pharmaceutical composition described herein and the kit described herein.
[0097] On the other hand, the present application provides the use of the crystalline form A described herein, the crystalline form B described herein, the pharmaceutical composition described herein and / or the kit described herein for inhibiting or preventing bacterial growth.
[0098] On the other hand, the present application provides the use of the crystalline form A described herein, the crystalline form B described herein, the pharmaceutical composition described herein and / or the kit described herein for preparing a drug, which is used to prevent, treat or alleviate diseases caused by bacterial infection or related conditions thereof.
[0099] On the other hand, the present application provides the pharmaceutical composition or the kit described herein, which is used to prevent, treat or alleviate diseases caused by bacterial infection or related conditions thereof.
[0100] Crystalline form of the free base of the compound of formula (I)
[0101] The present application provides Form A and Form B, and in some cases, Form C1, Form C2, and Form C3. The following examples will help further understand these forms described in the present application, their preparation methods, uses, and technical effects, etc., but these examples are not intended to limit the content of the invention of the present application.
[0102] Pharmaceutical composition
[0103] In some embodiments, the pharmaceutical compositions described herein can be prepared in any of the following forms: for example, the pharmaceutical compositions can be in the form of solutions, aerosols, gels, ointments, sprays, or suspensions, and the compositions in the above forms can be prepared using methods known and conventional in the art. For example, the pharmaceutically acceptable carrier can be selected from excipients for increasing solubility, adjuvants for increasing viscosity, and adjuvants for enhancing penetration.
[0104] In some embodiments, the pharmaceutical composition can also include a second therapeutic agent. For example, the second therapeutic agent can be selected from another rifamycin drug or its analog, a proton pump inhibitor, an acid suppressant, an efflux pump inhibitor, an anesthetic, an antifungal agent, an antiviral agent, an antibacterial agent, an antiprotozoal agent, an anti-inflammatory drug (such as a non-steroidal anti-inflammatory drug or a steroid), an anticoagulant, a platelet aggregation inhibitor, an antipyretic, a lipid-lowering agent, and a zinc salt. All therapeutic agents for the pharmaceutical composition described herein can be used within the dosage range currently known and used for these preparations.
[0105] Reagent test kit
[0106] In some embodiments, the kit described herein may include the crystalline form described herein and / or the pharmaceutical composition described herein; in addition, the kit may further include at least one container for placing the crystalline form and / or the pharmaceutical composition. For example, the kit may further include more than one component, and it may further include a second, third and / or other container other than the container, in which the more than one component may be placed separately. For example, the kit may also place various combinations of the crystalline form and / or the pharmaceutical composition in the container. For example, the kit may further include a buffer reagent, a device for mixing different components, a device for measuring, a device for sorting components and / or a device for labeling. For example, the kit may further include packaging for accommodating various containers. For example, the kit may also include instructions for using the kit components. For example, the instructions may include a physical paper form and / or a machine-readable electronic form.
[0107] Application method
[0108] In some embodiments, the method for inhibiting or preventing bacterial growth provided herein may include administering an effective amount of the crystalline form described herein, the pharmaceutical composition described herein, and / or the kit described herein by an optional route. In some embodiments, the method includes contacting the crystalline form described herein, the pharmaceutical composition described herein, and / or the kit described herein with a site infected by bacteria. For example, the site of infection may be within an animal, on an animal, within a plant, or on a plant.
[0109] In some embodiments, the method for preventing, treating or alleviating a disease or its related conditions provided herein may include administering an effective amount of the crystalline form described herein, the pharmaceutical composition described herein, and / or the kit described herein to a patient in need thereof in an optional manner. In certain embodiments, the method may further include mixing the crystalline form described herein, the pharmaceutical composition described herein, and / or the kit described herein with other therapeutic agents. In some embodiments, the method may include systemic delivery of the crystalline form described herein, the pharmaceutical composition described herein, and / or the kit described herein to a patient in need thereof, exposing it to a large part of the body. This step may be performed by any means known in the art, including but not limited to intravenous, intra-arterial, intracavitary, subcutaneous, and intraperitoneal delivery. In other embodiments, the method may include local delivery of the crystalline form described herein, the pharmaceutical composition described herein, and / or the kit described herein to a patient in need thereof, so that it directly reaches the target site in the organism or reaches the site of bacterial infection on the surface of the organism, or by direct contact with the surface site of the body infected by bacteria. For example, the local delivery does not exclude systemic pharmacological effects. In certain embodiments, the method may comprise administering an effective amount of the crystalline form described herein, the pharmaceutical composition described herein, and / or the kit described herein to a patient in need thereof by intramuscular injection, subcutaneous or intradermal injection, intravenous injection, intrathecal injection, inhalation, oral administration, or topical application.
[0110] Diseases caused by bacteria and bacterial infections or related conditions
[0111] In some embodiments, the patient in need described in the present application is infected by bacteria, or the patient in need suffers from a disease caused by bacterial infection or its related conditions. For example, the bacterium can be selected from: Helicobacter pylori, Mycobacterium tuberculosis, nontuberculous mycobacteria, Acinetobacter baumannii, Bacteroides fragilis, Bifidobacterium longum, Ruminococcus, Prevotella, Clostridium perfringens, Clostridium difficile, Lactobacillus acidophilus, Eggertella lentus, Fusobacterium nucleatum, Gardnerella vaginalis, Mobiluncus timidus, Peptostreptococcus, Porphyromonas nonsaccharolyticus, Prevotella diversa, Propionibacterium acnes and Veillonella parvum. In the present application, the bacterium may also include a resistant strain of the above-mentioned bacteria. For example, the resistant strain can be resistant to rifamycin alone, resistant to nitroimidazole alone, or resistant to rifamycin and nitroimidazole double. For example, the resistant strains may also be resistant to other antibiotics, including resistance to macrolides such as clarithromycin, azithromycin, and roxithromycin; resistance to fluoroquinolones such as ciprofloxacin, levofloxacin, and moxifloxacin; resistance to aminoglycosides such as streptomycin and amikacin; resistance to β-lactams such as ampicillin and amoxicillin; resistance to tetracyclines such as tetracycline, tigecycline, and minocycline; resistance to oxazolidinones such as linezolid and tedizolid; resistance to nitrofurans such as furazolidone; resistance to glycopeptides such as vancomycin; resistance to diarylquinolines such as bedaquiline and clofazimine, etc.
[0112] For example, the disease can be selected from gastritis, gastric ulcer, bacterial vaginosis, diarrhea, pneumonia, appendicitis, cholecystitis, otitis media, endocarditis, endometritis, brain abscess, myocardial necrosis, osteomyelitis, peritonitis, empyema, salpingitis, septic arthritis, liver abscess, sinusitis, pelvic inflammatory disease and bacteremia. For example, the condition can be selected from upper respiratory tract infection, lower respiratory tract infection, skin and soft tissue infection, bone and joint infection, lung infection, abdominal infection, eye infection, ear infection, oral infection and surgical infection.
[0113] Without intending to be bound by any theory, the following examples are merely intended to illustrate the crystal forms, preparation methods, and uses of the compounds of the present application, and are not intended to limit the scope of the present invention.
[0114] Example
[0115] Example 1
[0116] Preparation and characterization of Form A and Form B of this application
[0117] (1) Preparation of Form A
[0118] 40.05 g of the crude compound of formula (I) was weighed, mixed with 5 times the weight of methanol or ethanol, and stirred at 25 ° C for 30 minutes. At this time, obvious solid precipitation appeared. After continuing to stir for 2-3 hours, the wet cake was filtered and washed with 80 mL of methanol or ethanol. The wet cake was dried under vacuum at 42 ° C for 52 hours to finally obtain 36.12 g of crystalline product with a yield of about 67.9%. The purity of the crystalline product was 99.6% by high performance liquid chromatography (HPLC). The crystalline product was sampled and subjected to X-ray powder diffraction (XRPD) detection, thermogravimetric analysis (TGA), differential scanning calorimetry (DSC) analysis, liquid nuclear magnetic resonance hydrogen spectrum (Solution 1 H NMR) analysis and polarizing light microscopy (PLM) observation, the results are shown in Figure 1, Table 1, Figures 2A-2B, Figure 5, and Figures 6A-6B.
[0119] From the characterization results of Form A, it can be seen that the XRPD diffraction peaks (Figure 1) show that Form A has a high degree of crystallinity. 1 No residual solvent was observed by HNMR (Figure 5), suggesting that Form A is anhydrous and / or anhydrous. TGA / DSC results (Figures 2A-2B) showed that the Form A sample experienced a 1.36% weight loss upon heating to 150°C, with an endothermic peak at 169.3°C (peak temperature). PLM results (Figures 6A-6B) revealed that the sample was flat, rod-shaped with a particle size of approximately 10 to 50 μm.
[0120] Table 1 X-ray powder diffraction data of Form A
[0121] (2) Preparation of Crystal Forms C1-C3
[0122] 40.05 g of the crude compound of Formula (I) was weighed and mixed with 5 times the mass of ethanol. The mixture was stirred at 25°C for 30 minutes, at which point a clear solid precipitate appeared. After stirring for 2-3 hours, the wet cake was filtered and washed with 80 mL of ethanol. Three solvate crystalline forms C1, C2, and C3 with different structures were detected in the undried wet product of the compound of Formula (I) formed in ethanol. Their XRPD results are shown in Figures 9A-9C, Tables 2-1, 2-2, and 2-3. However, upon drying, Forms C1, C2, and C3 all converted to Form A, as shown in Figure 9D.
[0123] Table 2-1 X-ray powder diffraction data of Form C1
[0124] Table 2-2 X-ray powder diffraction data of Form C2
[0125] Table 2-3 X-ray powder diffraction data of Form C3
[0126] (3) Preparation of Form B
[0127] Form B was obtained by shaking the crystalline product (Form A) in Example (1) in toluene solvent at room temperature for 24 hours. After drying at room temperature for 24 hours, the crystalline form remained unchanged. The XRPD results are shown in Figure 3 and Table 3. The TGA / DSC results (Figures 4A-4B) showed that the sample of Form B had a weight loss of 9.33% when heated to 120°C and a weight loss of 5.36% when further heated to 150°C. The sample also had three endothermic peaks at 85.6°C, 130.7°C, and 144.3°C (peak temperatures). 1 H NMR results (Figure 7A) showed a molar ratio of residual solvent Toluene to API of 1.6 (13.5 wt%). To further investigate the significant TGA weight loss observed in the Form B sample, a heating experiment was performed. XRPD results (Figure 8) showed that the Form B sample remained unchanged after heating to 115°C and cooling to room temperature. However, the Form B sample converted to Form A after heating to 140°C and cooling to room temperature, albeit with poorer crystallinity. 1 H NMR results (Figures 7B and 7C) show that after heating the sample to 115°C and cooling to room temperature, the molar ratio of residual solvent, Toluene, to the API, was 1.2 (10.5 wt%). No residual Toluene solvent was detected after heating the sample to 140°C and cooling to room temperature. Due to the crystallization of the sample upon heating, combined with the significant TGA weight loss and residual solvent observed in the NMR results after heating, Form B is presumed to be a Toluene solvate.
[0128] Table 3 X-ray powder diffraction data of Form B
[0129] Example 2
[0130] Evaluation of Form A of this application
[0131] (1) Hygroscopicity test (dynamic water vapor sorption test or DVS)
[0132] DVS curves were collected on SMS (Surface Measurement Systems) DVS Intrinsic and DVS Intrinsic plus. Relative humidity at 25°C was calibrated using the deliquescence points of LiCl, Mg(NO3)2, and KCl. The DVS results (Figure 10) show that the Form A sample had a water adsorption of 2.880% at 25°C / 80% RH, indicating hygroscopicity. The amorphous form, under the same test conditions, had a hygroscopicity of 5.941%, indicating that Form A has superior hygroscopicity. Furthermore, XRPD results of Form A before and after DVS testing (Figure 11) show that no polymorphic transformation occurred, indicating that Form A exhibits superior stability. In contrast, Forms B, C1, C2, and C3 exhibited less stable forms and could be converted to Form A upon heating or drying.
[0133] (2) Solid stability
[0134] Form A samples were exposed at 60°C for 24 hours, and at 25°C / 60% RH and 40°C / 75% RH for one week. The physical and chemical stability of the samples was evaluated by XRPD and HPLC. The stability evaluation results are summarized in Table 4, with the XRPD results shown in Figure 12 and the HPLC results shown in Table 5 and Figure 13. The results show that Form A samples did not undergo significant purity changes or crystal form transformation after exposure to the three conditions.
[0135] Table 4 Summary of solid stability evaluation of Form A
[0136] Table 5 Summary of HPLC impurities of Form A solid stability samples
[0137] (3) Purification / impurity removal effect
[0138] This example also evaluates and compares the effects of Form A samples and amorphous samples of the compound of formula (I) in the purification and impurity removal process of the crude compound of formula (I).
[0139] Amorphous beating step: weigh about 0.5g of the compound of formula (I) into a 25mL glass bottle equipped with magnetic stirring, add 5mL of different solvents, and the mixture is beating at room temperature, filtered, and the filter cake is taken to detect purity by high performance liquid chromatography. Among them, the selection of different solvents is to mix a solvent with high solubility for the compound of formula (I) (for example, methanol, ethanol, isopropanol, acetone, acetonitrile, ethyl acetate (EA), isopropyl acetate (IPAC), tetrahydrofuran (THF), toluene, dichloromethane (DCM), dimethylformamide (DMF), 2-methyltetrahydrofuran (2-MeTHF), dimethyl sulfoxide (DMSO) etc.) with a solvent with low solubility for the compound of formula (I) (for example, water, methyl tert-butyl ether (MTBE) and n-heptane), and screen out a solvent system that can precipitate solids. The selected amorphous beating solvent system and its corresponding purification effect are shown in Table 6.
[0140] Purification step of Form A: Weigh 3.5 g of the crude product of the compound of formula (I) into a 50 mL reaction bottle equipped with a magnetic stirrer, add 17.5 mL of ethanol, and stir the mixture at 25 ° C. for 15 minutes. Filter, rinse the filter cake with 5 mL of ethanol, and dry the wet product under vacuum to obtain the crystalline compound of formula (I). The purity is detected by high performance liquid chromatography.
[0141] Table 6 Summary of purification effects of amorphous form and crystal form A
[0142] The comparison of the effects of the two purification methods is summarized in Table 6. It can be seen that compared with the HPLC results of the crude product of the compound of formula (I), the use of various solvent mixture systems to slurry and purify the amorphous sample has basically no impurity removal effect. In contrast, the purification effect of Form A is significant. It can not only increase the purity of the crude product before purification from 92.95% to 98.2%, but also completely remove individual impurities such as RRT0.54, RRT0.92, RRT0.97 and RRT1.08. For impurities that are difficult to remove by the amorphous slurry method, such as RRT0.63, RRT0.85, RRT0.92, RRT0.95, RRT0.97 and RRT1.21, the purification method of Form A crystallization has a more significant purification effect than that of the amorphous form.
[0143] The purification method of column chromatography followed by ethanol / water slurrying and the crystal form A crystallization method were simultaneously investigated for their ability to remove impurities that are difficult to remove, as shown in Table 7. The results showed that for impurities RRT0.83 and RRT0.98 that are difficult to remove by column chromatography, Form A has a relatively good impurity removal effect; especially for impurity RRT0.98 (the structural formula is shown in Figure 14), the crystallization method of Form A can control it below the detection line. On the other hand, the purification method of column chromatography is time-consuming and labor-intensive, with high production costs, high process equipment requirements, and difficulty in controlling impurities. The crystallization purification method using Form A is more environmentally friendly and has advantages in reducing production costs.
[0144] Table 7 Summary of the purification effects of amorphous phase after column chromatography and crystallization of Form A
Claims
1. Form A of the free base of the compound represented by formula (I), The X-ray powder diffraction of the crystalline form A has characteristic peaks at diffraction angles 2θ of 5.28°±0.2°, 7.17°±0.2°, 8.50°±0.2°, 10.66°±0.2°, 14.33°±0.2°, 15.84°±0.2° and 18.60°±0.2°.
2. The crystalline form A according to claim 1, wherein the crystalline form A has characteristic peaks at one or more of the diffraction angle 2θ values of 12.61°±0.2°, 14.83°±0.2°, 15.26°±0.2°, 16.57°±0.2°, 19.97°±0.2° and 21.97°±0.2°.
3. According to the crystalline form A according to any one of claims 1-2, the crystalline form A has characteristic peaks at diffraction angle 2θ values of 12.61°±0.2°, 14.83°±0.2°, 15.26°±0.2°, 16.57°±0.2°, 19.97°±0.2° and 21.97°±0.2°.
4. The crystalline form A according to any one of claims 1 to 3, wherein the X-ray powder diffraction (XRPD) pattern of the crystalline form A is substantially consistent with that of FIG. 1 .
5. A crystalline form A of the free base of the compound represented by formula (I), wherein the differential scanning calorimetry curve of the crystalline form A has an endothermic peak at about 169.3°C.
6. The crystalline form A according to claim 5, wherein the differential scanning calorimetry (DSC) graph of the crystalline form A is substantially consistent with that of FIG. 2B .
7. The crystalline form A according to any one of claims 1 to 6, wherein the crystalline form A is an anhydrate and / or ansolvate-free form.
8. A crystalline form B of the free base of the compound represented by formula (I), wherein the X-ray powder diffraction of the crystalline form B has characteristic peaks at diffraction angles 2θ of 4.89°±0.2°, 6.67°±0.2°, 7.12°±0.2°, 13.41°±0.2°, 14.62°±0.2°, 15.19°±0.2° and 18.23°±0.2°.
9. The crystalline form B according to claim 8, wherein the X-ray powder diffraction of the crystalline form B has characteristic peaks at one or more of the diffraction angles 2θ of 7.84°±0.2°, 10.67°±0.2°, 14.25°±0.2°, 16.07°±0.2°, 17.10°±0.2°, 17.41°±0.2°, 17.74°±0.2° and 20.73°±0.2°.
10. The crystal form B according to any one of claims 8 to 9, wherein the X-ray powder diffraction of the crystal form B has characteristic peaks at diffraction angles 2θ of 7.84°±0.2°, 10.67°±0.2°, 14.25°±0.2°, 16.07°±0.2°, 17.10°±0.2°, 17.41°±0.2°, 17.74°±0.2° and 20.73±0.2°.
11. The crystalline form B according to any one of claims 8 to 10, wherein the X-ray powder diffraction (XRPD) pattern of the crystalline form B is substantially consistent with FIG. 3 .
12. A crystalline form B of the free base of the compound represented by formula (I), wherein the differential scanning calorimetry curve of the crystalline form B has endothermic peaks at about 85.6°C, about 130.7°C and about 144.3°C.
13. The crystalline form B according to claim 12, wherein the differential scanning calorimetry (DSC) graph of the crystalline form B is substantially consistent with FIG. 4B .
14. The crystalline form B according to any one of claims 8 to 13, which is obtained by converting the crystalline form A according to any one of claims 1 to 7 in a toluene reagent.
15. The crystalline form B according to any one of claims 8 to 14, wherein the crystalline form B is a toluene solvate.
16. The crystal form B according to any one of claims 8 to 15, wherein the molar ratio of the compound represented by formula (I) to toluene molecules in the crystal form B is 1:2 to 1:
1.
17. A pharmaceutical composition comprising the crystalline form A according to any one of claims 1 to 7 and / or the crystalline form B according to any one of claims 8 to 16, and optionally a pharmaceutically acceptable carrier.
18. The pharmaceutical composition of claim 17, further comprising a second therapeutic agent.
19. The pharmaceutical composition of claim 18, wherein the second therapeutic agent is selected from the group consisting of proton pump inhibitors, acid suppressants, efflux pump inhibitors, anesthetics, antifungals, antivirals, antibacterials, antiprotozoals, anti-inflammatory drugs, anticoagulants, platelet aggregation inhibitors, antipyretics, lipid-lowering agents, and zinc salts.
20. A kit comprising one or more of the crystalline form A according to any one of claims 1 to 7, the crystalline form B according to any one of claims 8 to 16, and the pharmaceutical composition according to any one of claims 17 to 19.
21. The kit according to claim 20, further comprising instructions for use in physical form and / or in machine-readable electronic form.
22. A method for preparing a drug using the crystalline form A according to any one of claims 1 to 7 and / or the crystalline form B according to any one of claims 8 to 16.
23. A method for inhibiting or preventing bacterial growth, the method comprising administering an effective amount of one or more of the crystalline form A of any one of claims 1-7, the crystalline form B of any one of claims 8-16, the pharmaceutical composition of any one of claims 17-19, and the kit of any one of claims 20-21.
24. A method for preventing, treating or alleviating a disease or a condition related thereto, the method comprising administering to a patient in need thereof an effective amount of one or more of the crystalline form A of any one of claims 1 to 7, the crystalline form B of any one of claims 8 to 16, the pharmaceutical composition of any one of claims 17 to 19, and the kit of any one of claims 20 to 21.
25. The method of claim 24, wherein the patient in need thereof is infected with a bacteria.
26. The method according to any one of claims 23-25, wherein the bacteria is selected from the group consisting of Helicobacter pylori, Mycobacterium tuberculosis, nontuberculous mycobacteria, Acinetobacter baumannii, Bacteroides fragilis, Bifidobacterium longum, Ruminococcus, Prevotella, Clostridium perfringens, Clostridium difficile, Lactobacillus acidophilus, Eggertella lentus, Fusobacterium nucleatum, Gardnerella vaginalis, Mobiluncus timidus, Peptostreptococcus, Porphyromonas insaccharolyticus, Prevotella diversus, Propionibacterium acnes and Veillonella parvum.
27. Use of the crystalline form A according to any one of claims 1 to 7, the crystalline form B according to any one of claims 8 to 16, the pharmaceutical composition according to any one of claims 17 to 19, and / or the kit according to any one of claims 20 to 21 for inhibiting or preventing bacterial growth.
28. Use of the crystalline form A according to any one of claims 1 to 7, the crystalline form B according to any one of claims 8 to 16, the pharmaceutical composition according to any one of claims 17 to 19, and / or the kit according to any one of claims 20 to 21 for preparing a drug for preventing, treating or alleviating a disease caused by a bacterial infection or a related condition thereof.
29. The use according to any one of claims 27-28, wherein the bacteria is selected from the group consisting of Helicobacter pylori, Mycobacterium tuberculosis, nontuberculous mycobacteria, Acinetobacter baumannii, Bacteroides fragilis, Bifidobacterium longum, Ruminococcus, Prevotella, Clostridium perfringens, Clostridium difficile, Lactobacillus acidophilus, Eggertella lentus, Fusobacterium nucleatum, Gardnerella vaginalis, Mobiluncus timidus, Peptostreptococcus, Porphyromonas insaccharolyticus, Prevotella diversus, Propionibacterium acnes and Veillonella parvum.
30. The use according to any one of claims 28-29, wherein the disease or its related condition is selected from: gastritis, gastric ulcer, bacterial vaginosis, diarrhea, pneumonia, appendicitis, cholecystitis, otitis media, endocarditis, endometritis, brain abscess, myocardial necrosis, osteomyelitis, peritonitis, empyema, salpingitis, septic arthritis, liver abscess, sinusitis, pelvic inflammatory disease and bacteremia; and upper respiratory tract infection, lower respiratory tract infection, skin and soft tissue infection, bone and joint infection, lung infection, abdominal infection, eye infection, ear infection, oral infection and surgical infection.
31. The pharmaceutical composition according to any one of claims 17 to 19 or the kit according to any one of claims 20 to 21, wherein the pharmaceutical composition or the kit is used to prevent, treat or alleviate a disease caused by a bacterial infection or a related condition thereof.
32. A method for preparing the crystalline form A according to any one of claims 1 to 7, the method comprising crystallizing the compound represented by formula (I) in a solvent comprising an alcohol solvent.
33. The method according to claim 32, wherein the alcohol solvent is selected from one or a combination of more than one of methanol, ethanol, n-propanol, isopropanol, n-butanol, isobutanol and tert-butanol.
34. The method according to any one of claims 32-33, wherein the alcohol solvent is methanol, ethanol or a combination thereof.
35. The method according to any one of claims 32 to 34, wherein crystallizing in a solvent comprising an alcohol solvent is further crystallizing in an alcohol solvent.
36. A method for preparing the crystalline form B according to any one of claims 8-16, the method comprising crystallizing the crystalline form A according to any one of claims 1-7 in a toluene solvent.
